Akorn, Inc. (AKN) Announces the Approval and Launch of Generic Vancocin®  
4/10/2012 10:03:44 AM

LAKE FOREST, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ: AKRX), a niche specialty pharmaceutical company, today announced that it has launched Vancomycin Hydrochloride USP 125mg and 250mg capsules, the generic version of ViroPharma’s Vancocin®, which is indicated for the treatment of Clostridium difficile-associated diarrhea (CDAD). Vancocin® is also used for the treatment of enterocolitis caused by Staphylococcus aureus including methicillin-resistant strains.